<?xml version="1.0" encoding="UTF-8" ?>
<MyRCT>
<TEXT><![CDATA[Alectinib Superior to Crizotinib for ALK+ NSCLC.
Findings from the global phase III ALEX trial unequivocally show that alectinib is superior to crizotinib as first-line therapy for ALK+ non-small cell lung cancer.
Alectinib more than doubled progression-free survival, significantly reduced the incidence of brain and CNS metastases, and should be considered the new standard of care.]]></TEXT>
<TAGS>
<LiteratureClassification id="L0" spans="-1~-1" text="" format="other" population="" purpose="" biomarker=""/>
</TAGS>
<META/>
</MyRCT>